Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Femasys Inc.
Femasys Announces Financial Results for Quarter Ended June 30, 2024 and Provides Corporate Update
August 08, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
June 27, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Receives CE Mark Approval for Four of its Women’s Health Products Clearing the Path for the Company to Begin Commercialization Efforts in Europe
June 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Office of Science and Technology Policy to Discuss the Cancer Moonshot Initiative
May 17, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with the White House’s Gender Policy Council
May 16, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Quarter Ended March 31, 2024 and Provides Corporate Update
May 09, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Expands Commercial Management Team with Addition of Experienced New Hires
May 07, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
April 18, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
March 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
March 21, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
March 20, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
March 13, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
March 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
February 28, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Advances Commercial Readiness with Appointment of Richard Spector to New Position of Chief Commercial Officer
February 06, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at UC Davis Medical Center, a Hub for Innovation and Groundbreaking Research in Health Care for Women
January 26, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at University of Utah, an Internationally Recognized Center in Obstetrics and Gynecology
January 23, 2024
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Begins FemBloc Pivotal Trial Enrollment at Stanford Medicine
December 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Announces the Appointment of James Liu, M.D., as Chief Medical Officer
November 30, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
November 28, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Secures Additional Financing with Strategic Investment from Investors led by PharmaCyte Biotech
November 15, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
PMCB
Femasys Inc. Announces Financial Results for the Third Quarter Ended September 30, 2023 and Provides Corporate Update
November 14, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. EU MDR Final Audit Successfully Completed
October 26, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. to Showcase FemBloc and its other Novel Products Advancing Women’s Health at the American Association of Gynecologic Laparoscopic Surgeons
October 25, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Regains Compliance with Nasdaq Listing Requirements
October 11, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. to Showcase FemaSeed at the Annual Meeting of the American Society of Reproductive Medicine
October 04, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. MDSAP Surveillance Audit Successfully Completed
October 03, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Expands FemBloc Pivotal Trial Enrollment Securing First Academic Site to Participate
September 27, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Inc. Receives U.S. FDA Clearance to Market FemaSeed, an Innovative Infertility Treatment Solution
September 25, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Femasys Announces First-Patient-In for Pivotal Clinical Trial Evaluating its FemBloc Permanent Birth Control
September 20, 2023
From
Femasys Inc.
Via
GlobeNewswire
Tickers
FEMY
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.